Actively Recruiting
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
Led by Dana-Farber Cancer Institute · Updated on 2025-08-07
5000
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a study to gather and store samples and information from individuals who might be at higher risk of developing cancer or have early-stage cancer or precursor conditions, as well as their family members. The study aims to identify exposures and clinical, molecular, and pathological changes that help predict early cancer development, progression, and malignant transformation. The ultimate goal is to find new markers for early detection and risk assessment that could guide future treatments to prevent cancer progression. Participants will provide tissue samples during routine visits, including blood, saliva or mouthwash, urine, stool, biopsy or surgical tissue such as bone marrow, bodily fluids, or other tissues. Participants will also complete a survey about their demographics, medical history, and family history. Family members of participants may also provide blood or saliva samples through various collection methods, including at consent, by mail, or at a separate appointment. During the study, participants will have clinical information and specimens collected for research analysis. Researchers will monitor exposures and changes over five years to understand cancer risk and progression. About 5,000 people are expected to participate. The study includes data collection from questionnaires, tissue sampling, and molecular analysis to identify markers that predict cancer development and progression. Participants' health and safety are monitored throughout the study period, which can last several years.
CONDITIONS
Brief Title
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with hereditary risk for cancer including carriers of pathogenic germline variants of cancer-related genes
- Individuals with personal or family history suggestive of elevated cancer risk
- Individuals clinically diagnosed with a Cancer Predisposition Syndrome (e.g., neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)
- Individuals with elevated cancer risk based on hereditary cancer prediction models
- Others at risk due to exposure, obesity, gender, race, ethnicity, or HPV exposure
- Childhood cancer survivors with treatment exposures linked to increased cancer risk
- Adult cancer survivors with treatment exposures linked to increased cancer risk
- Individuals with documented high-level exposure to group 1 IARC carcinogens
- Individuals at risk for lung cancer (age >50, smoking history >15 pack years, family history of lung cancer or COPD)
- Individuals with alcoholic liver disease, non-alcoholic steatohepatitis, or cirrhosis
- Participants with precursor lesions in various organs such as breast, GI tract, genitourinary system, lung, head and neck, skin, hematologic malignancies, thoracic nodules, gynecologic lesions, or pediatric histologic diagnoses associated with malignancy
- Family members or healthy individuals related to participants
You will not qualify if you...
- There are no exclusion criteria for this study
- Patients with prior cancer history, including non-metastatic localized cancers, are allowed
- Participants enrolled in clinical trials or receiving therapy for precursor diseases are not excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are observed and clinical information is collected during routine healthcare visits. Tissue samples such as blood, buccal swabs, urine, stool, biopsy or surgical tissue, and bodily fluids are collected for research purposes.
Visits occur during routine healthcare appointments; timing may vary
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
J
Jenna Beckwith, MPH
T
Tia Kauffman, MPH
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here